Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation
SAN DIEGO, Dec. 3, 2019/PRNewswire/ -- Viriom Inc (Viriom) announces launching Segment I and SegmentII reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy,supported by preclinical services of the Division of AIDS at the NationalInstitute of Allergy and Infectious Diseases, part of the National Institutesof Health.
These preclinical studies arecritical for the Food and Drug Administration (FDA) drug approval process andfor bringing Elpida® once weekly oral formulation to the market in the UnitedStates. The studies are executed by SRI International (www.sri.com) and Covance(www.covance.com).
About Elpida® (elsulfavirine):Elsulfavirine is an investigational new drug that is being studied in oncedaily and once weekly oral long-acting formulations to treat HIV. Elsulfavirinebelongs to a group of HIV drugs called non-nucleoside reverse transcriptaseinhibitors (NNRTIs). NNRTIs attach to and block an HIV enzyme called reversetranscriptase. Studies have shown that elsulfavirine appears effective fortreating HIV in people who have not previously taken HIV medicines.Elsulfavirine may also be effective against certain strains of HIV that can nolonger be controlled by Food and Drug Administration (FDA)-approved NNRTIs.Viriom is also developing a long-acting injectable formulation ofinvestigational new drug VM1500A-LAI to prevent HIV.
About Viriom: Viriom (SanDiego, CA) focuses on the treatment, prophylaxis, and eradication of infectiousdiseases globally. Viriom is developing and commercializing the most innovativeand affordable solutions to radically expand global access to the bestantiviral treatments. Viriom's broad, proprietary, and partnered pipelinecovers therapeutic, prophylactic, and curative medicines for HIV and viralhepatitis. Learn more at www.viriom.com.
Media Contact: Iain Dukes CEO, Viriom Inc +1 (212) 739-6444